These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 23358899)

  • 21. Individualized anemia management in a dialysis facility - long-term utility as a single-center quality improvement experience
.
    Gaweda AE; Jacobs AA; Aronoff GR; Brier ME
    Clin Nephrol; 2018 Oct; 90(4):276-285. PubMed ID: 30049300
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of erythropoietin for treatment of anemia in chronic kidney failure- ESRD patients.
    Srinivasan R; Fredy IC; Chandrashekar S; Saravanan J; Mohanta GP; Manna PK
    Biomed Pharmacother; 2016 Aug; 82():44-8. PubMed ID: 27470337
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical efficacy of recombinant human erythropoietin in the treatment of anemia in hemodialysis patients: influence of dosing regimen, iron status, and serum aluminum.
    Tsai JC; Lai YH; Tsai ZY; Chien LJ; Tsai JH
    Gaoxiong Yi Xue Ke Xue Za Zhi; 1991 Mar; 7(3):126-35. PubMed ID: 1865507
    [TBL] [Abstract][Full Text] [Related]  

  • 24. T-Wave Alternans, Heart Rate Turbulence, and Ventricular Ectopy in Standard versus Daily Hemodialysis: Results from the FHN Daily Trial.
    Kaplan RM; Herzog CA; Larive B; Subacius H; Nearing BD; Verrier R; Passman RS
    Ann Noninvasive Electrocardiol; 2016 Nov; 21(6):566-571. PubMed ID: 27778458
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Baseline characteristics of participants in the Frequent Hemodialysis Network (FHN) daily and nocturnal trials.
    Rocco MV; Larive B; Eggers PW; Beck GJ; Chertow GM; Levin NW; Kliger AS;
    Am J Kidney Dis; 2011 Jan; 57(1):90-100. PubMed ID: 21122961
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anemia Management among Hemodialysis Patients with High Ferritin Levels.
    Einbinder Y; Agur T; Davidov K; Zitman-Gal T; Golan E; Benchetrit S
    Isr Med Assoc J; 2018 Jul; 20(7):405-411. PubMed ID: 30109787
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hemoglobin response and influence on left ventricular hypertrophy after 24-week treatment of a biosimilar epoetin-alfa in hemodialysis patients with anemia.
    Thanakitcharu P; Siriwiwatanakul N
    J Med Assoc Thai; 2007 Dec; 90(12):2574-86. PubMed ID: 18386706
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical experience with darbepoietin alfa (NESP) in children undergoing hemodialysis.
    De Palo T; Giordano M; Palumbo F; Bellantuono R; Messina G; Colella V; Caringella AD
    Pediatr Nephrol; 2004 Mar; 19(3):337-40. PubMed ID: 14745634
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An observational cohort study of extended dosing (once every 2 weeks or once monthly) regimens with darbepoetin alfa in patients with chronic kidney disease not on dialysis: the EXTEND study.
    Galle JC; Claes K; Kiss I; Winearls CG; Herlitz H; Guerin A; Di Giulio S; Suranyi MG; Bridges I; Addison J; Farouk M
    Nephrol Dial Transplant; 2012 Jun; 27(6):2303-11. PubMed ID: 22140136
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral zinc supplementation reduces the erythropoietin responsiveness index in patients on hemodialysis.
    Kobayashi H; Abe M; Okada K; Tei R; Maruyama N; Kikuchi F; Higuchi T; Soma M
    Nutrients; 2015 May; 7(5):3783-95. PubMed ID: 25988769
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New Options for Iron Supplementation in Maintenance Hemodialysis Patients.
    Vaziri ND; Kalantar-Zadeh K; Wish JB
    Am J Kidney Dis; 2016 Mar; 67(3):367-75. PubMed ID: 26616335
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of achieved hemoglobin level on renal outcome in non-dialysis chronic kidney disease (CKD) patients receiving epoetin beta pegol: MIRcerA CLinical Evidence on Renal Survival in CKD patients with renal anemia (MIRACLE-CKD Study).
    Hayashi T; Uemura Y; Kumagai M; Kimpara M; Kanno H; Ohashi Y;
    Clin Exp Nephrol; 2019 Mar; 23(3):349-361. PubMed ID: 30291472
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of increased frequency of hemodialysis on serum cystatin C and β2-microglobulin concentrations: A secondary analysis of the frequent hemodialysis network (FHN) trial.
    Huang SS; Kaysen GA; Levin NW; Kliger AS; Beck GJ; Rocco MV; Filler G; Lindsay RM;
    Hemodial Int; 2019 Jul; 23(3):297-305. PubMed ID: 30861262
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of 6-times-weekly versus 3-times-weekly hemodialysis on depressive symptoms and self-reported mental health: Frequent Hemodialysis Network (FHN) Trials.
    Unruh ML; Larive B; Chertow GM; Eggers PW; Garg AX; Gassman J; Tarallo M; Finkelstein FO; Kimmel PL;
    Am J Kidney Dis; 2013 May; 61(5):748-58. PubMed ID: 23332990
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Human recombinant erythropoietin in the treatment of anemia in patients on long-term hemodialysis].
    Boratyńska M; Szewczyk Z; Szepietowski T; Czyz W; Cybulski K; Bogucki J; Szczepański J
    Przegl Lek; 1990; 47(11):741-5. PubMed ID: 2098840
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current management of anemia in adult hemodialysis patients with end-stage renal disease.
    Frankenfield DL; Johnson CA
    Am J Health Syst Pharm; 2002 Mar; 59(5):429-35. PubMed ID: 11887409
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cumulative iron dose and resistance to erythropoietin.
    Rosati A; Tetta C; Merello JI; Palomares I; Perez-Garcia R; Maduell F; Canaud B; Aljama Garcia P
    J Nephrol; 2015 Oct; 28(5):603-13. PubMed ID: 25091785
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Assessment of iron requirements during treatment of anemia with recombinant human erythropoietin in patients with chronic renal insufficiency under hemodialysis].
    Oliveira C; Boquinhas H; Gaspar A; Adragão T; Boquinhas JM; Júnior EC; Simões J
    Acta Med Port; 1992 Jul; 5(7):351-7. PubMed ID: 1442178
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduced requirement for erythropoietin with quotidian hemodialysis therapy.
    Klarenbach S; Heidenheim AP; Leitch R; Lindsay RM;
    ASAIO J; 2002; 48(1):57-61. PubMed ID: 11814098
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The importance of iron in long-term survival of maintenance hemodialysis patients treated with epoetin-alfa and intravenous iron: analysis of 9.5 years of prospectively collected data.
    Pollak VE; Lorch JA; Shukla R; Satwah S
    BMC Nephrol; 2009 Feb; 10():6. PubMed ID: 19245700
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.